MX2022014080A - Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor). - Google Patents

Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor).

Info

Publication number
MX2022014080A
MX2022014080A MX2022014080A MX2022014080A MX2022014080A MX 2022014080 A MX2022014080 A MX 2022014080A MX 2022014080 A MX2022014080 A MX 2022014080A MX 2022014080 A MX2022014080 A MX 2022014080A MX 2022014080 A MX2022014080 A MX 2022014080A
Authority
MX
Mexico
Prior art keywords
actriib
methods
mtor
rapamycin
inhibitors
Prior art date
Application number
MX2022014080A
Other languages
English (en)
Spanish (es)
Inventor
Melih Acar
Martin Schwickart
Madhulika Jupelli
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022014080A publication Critical patent/MX2022014080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022014080A 2020-05-15 2021-05-14 Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor). MX2022014080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025955P 2020-05-15 2020-05-15
PCT/US2021/032434 WO2021231851A1 (en) 2020-05-15 2021-05-14 Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors

Publications (1)

Publication Number Publication Date
MX2022014080A true MX2022014080A (es) 2022-12-07

Family

ID=78525025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014080A MX2022014080A (es) 2020-05-15 2021-05-14 Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor).

Country Status (11)

Country Link
US (1) US20230210827A1 (https=)
EP (2) EP4649961A3 (https=)
JP (1) JP2023526590A (https=)
KR (1) KR20230010641A (https=)
CN (1) CN115551487A (https=)
AU (1) AU2021273065A1 (https=)
BR (1) BR112022022830A2 (https=)
CA (1) CA3177632A1 (https=)
IL (1) IL298156A (https=)
MX (1) MX2022014080A (https=)
WO (1) WO2021231851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CA3001654A1 (en) * 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
MA45811A (fr) * 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
PL3638243T3 (pl) * 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
EP4041243A4 (en) * 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE

Also Published As

Publication number Publication date
EP4649961A2 (en) 2025-11-19
IL298156A (en) 2023-01-01
CA3177632A1 (en) 2021-11-18
EP4149441A1 (en) 2023-03-22
JP2023526590A (ja) 2023-06-22
CN115551487A (zh) 2022-12-30
US20230210827A1 (en) 2023-07-06
WO2021231851A1 (en) 2021-11-18
BR112022022830A2 (pt) 2022-12-13
EP4649961A3 (en) 2026-02-25
EP4149441A4 (en) 2024-03-13
KR20230010641A (ko) 2023-01-19
AU2021273065A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
SA520420458B1 (ar) نظائر رابامايسين مرتبطة بـ C40، C28، وC32 mTOR كمثبطات
MX2022014080A (es) Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor).
MX2022003414A (es) Celulas efectoras con multiples objetivos y uso de las mismas.
CR20200347A (es) Inhibidores pd-1/pd-l1
Nakamura et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9
MY205645A (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2017009003A (es) Preparados combinados para el tratamiento contra el cancer o infecciones.
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
MX2024004162A (es) Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico.
HK1210786A1 (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX2024010373A (es) Metodos y composiciones para el tratamiento de la hipertension pulmonar.
Mandili et al. Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation
ZA202107139B (en) Methods and compositions for treating cancer
MX2024011348A (es) Inhibidor de la interacción proteína-proteína mll1-wdr5 de feniltriazol.
ATE553764T1 (de) Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
MX2023014139A (es) Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b.
EA201792286A1 (ru) Способы лечения рака
EA201490766A1 (ru) Комбинированная терапия рака яичников